Hi, How Are You?
↻
Let's Get Started
Forgot Password?
Sign Up
EN
Home
Article
Events
All Events
Webinar
new!
Product & Disease
Product
Disease
Pharmacovigilance
Medical Calculator
new!
Education
MOOC
CDK
Multimedia
FAQ & Feedback
Discussions
About Us
Login
Register
Product
Profile
PRODUCTS
DISEASE
PHARMACOVIGILANCE
MEDCAL
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
PIONIX
BRANDED
Pioglitazone works to reduce insulin resistance, activates specific nucleus receptors (peroxisome proliferator activated receptor gamma), which will increase insulin sensitivity in the liver, fat tissue and skeletal muscle cells.
Available at :
Share this article
Related
Articles
Insulin Glulisine in Pregnancy: Insights from Clinical Trial and Post Marketing Surveillance
by dr. Verawati Nur | 29 Sep 2025
Simplification of T2DM Therapy with iGlarLixi: A Single Injection for Optimal Glycemic Control Throughout the Day
by dr. Alfredo Bambang, MBA | 26 Aug 2025
Are Stem Cells Potentially Effective in Type 1 Diabetes?
by dr. Hastarita Lawrenti | 25 Jul 2025
Efficacy and Safety of Second-Generation Basal Insulin in DM Patients with Impaired Renal Function
by dr. Alfredo Bambang, MBA | 24 Jul 2025
Pregabalin Appropriate for Diabetic Peripheral Neuropathy Patients with Higher HbA1c, Study Finds
by dr. Hastarita Lawrenti | 01 Jul 2025
.
by dr. Hastarita Lawrenti | 12 Mar 2025
Strategies for Managing Type 2 Diabetes with FRC Iglarlixi During Ramadan Fasting
by dr. Risya Malida | 18 Feb 2025
Potential Use of Stem Cells in Type 2 Diabetes Mellitus Patients
by dr. Hastarita Lawrenti | 21 Mar 2025
Effectiveness of IGlarLixi in Improving Glycemic Control Based on Continuous Glucose Monitoring
by dr. Alfredo Bambang, MBA | 20 Dec 2024
RESTORE-G Data: 40% of T2DM Patients on GLP-1 RA Require Intensification After 2 Years
by dr. Alfredo Bambang, MBA | 17 Dec 2024
×
Subscribe Status
Generals
Articles
CPD/CME & CDK
Events & Webinar
SAVE